An inhibitor targeting the RAS pathway, which is commonly mutated in cancer, could change the way doctors treat pancreatic ...

Growing momentum for RAS inhibition at ASCO highlights Namodenoson’s RAS pathway inhibition and encouraging data in ...

A new wave of scientific understanding is placing ferroptosis, a distinct form of iron-dependent cell death, at the forefront ...

ASCO 2026 cancer breakthroughs from Chicago include daraxonrasib nearly doubling survival in metastatic pancreatic cancer, ...

NSCLC showed the largest reduction in metastatic progression with GLP-1RAs versus gliptins (HR 0.50), with significant ...

For most children diagnosed with medulloblastoma, the most common malignant pediatric brain tumor, survival rates are encouraging. But for a subset, remission is not the end of the story. Roughly 30% ...

A Cleveland Clinic study finds Ozempic-style GLP-1 drugs may significantly slow the spread of several obesity-related cancers ...

A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications ...

GLP-1 medications are drugs that mimic a natural hormone in the body called glucagon-like peptide-1, which helps regulate ...

SEATTLE — Since 2005, Cancer Pathways has been going into as many school classrooms to share life-saving information. Cancer Pathways, formerly Gilda's Club Seattle, has made it a goal to reach as ...